Regeneron Pharmaceuticals

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505
Regeneron desde 1990 ha dado un 3000% de rentabilidad, mira su pipeline, tienen un arsenal de fármacos , unos en fases tempranas, otros comercializándose, otros en fases avanzadas.

 

Himbersor hintelijente

Lonchafinista
Desde
26 Abr 2021
Mensajes
174
Reputación
310
Yo la compre a 487 y vendi a 497 porque me entro miedo por las patentes. Soy gilipollas. Ahora llevaria un 25% de rentabilidad si no hubiera vendido. Encima te tengo aqui recordandolo. La madre que te pario.
 

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505
Regeneron (REGN) Upgraded to Strong Buy: Here's Why
Zacks Equity Research
July 2, 2021, 6:00 pm

Regeneron (REGN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

As such, the Zacks rating upgrade for Regeneron is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
 

austral

Himbersor
Desde
30 Ago 2017
Mensajes
1.315
Reputación
681
En mi opinión, muy cara
Cotiza a 584$
Capitaliza 62000 millones
Esta mejor que hace 6 meses, pero no ha mejorado nada con respecto a 1 año
Hay mejores posibilidades en el mercado
 
Última edición:

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505
Para mi nada de cara y ya verás donde la veremos
Ademas, que tiene que ver la cotización hace un año?
Que métrica usas para verla cara?
Eso ya lo dijeron con un 30% mas baratas sin explicación alguna. Y muchas me dicen eso y después un 100%. Mala valoración veo de la mayoria
 

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505
P/E 2021 de 12 veces
EV/EBITDA de 8
ROE 35%
EV/ingresos de 4 veces

Margen neto el 41%. Y dices cara, ja,ja. Es un chollo de los que me encantan cuando otros no lo ven
 

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505
Aqui hay futuro para medio plazo por los contagios de covid, es el mejor fármaco hasta ahora y las ventas se están disparando
 

SEVILLA2014

Madmaxista
Desde
12 Mar 2015
Mensajes
6.349
Reputación
2.505
Regeneron Pharmaceuticals plans to add 1,000 jobs over the next five years at its Tarrytown, NY, headquarters, under a $1.8 billion expansion in which the company also plans to add to its research, preclinical manufacturing, and support facilities.

Depending how close it comes to fulfilling its 1,000-job goal, Regeneron could receive up to $100 million in Excelsior Jobs Program tax credits from New York state, among other state and local economic incentives.

The expansion plan, announced Thursday by Regeneron and New York state Gov. Andrew Cuomo (D), caps 18 months during which the company gained global attention through the development of its two-antibody “cocktail” REGEN-COV™—which was authorized for emergency use by the FDA and taken last year by then-President Donald Trump among several treatments for COVID-19.

In 2020, Regeneron recorded significant year-over-year sales gains for marketed drugs that include Eylea® (aflibercept; co-marketed with Bayer) and Dupixent® (dupilumab; co-marketed with Sanofi), while in February, it received FDA approval for two additional indications for its cancer drug Libtayo® (cemiplimab-rwlc), in forms of advanced basal cell carcinoma and advanced non-small cell lung cancer.

“The COVID-19 pandemic has highlighted the importance of continued and long-term investment in the biopharmaceutical industry, and Regeneron is proud to pursue life-changing science and technology from our labs and manufacturing facilities in New York State,” Regeneron president and CEO Leonard S. Schleifer, MD, PhD, said in a statement.


Regeneron has nearly 10,000 employees worldwide—including approximately 3,800 at its Tarrytown headquarters.

In addition to the Tarrytown HQ, Regeneron’s New York state presence includes offices 3 miles northwest in Sleepy Hollow, NY; and the company’s industrial operations and product supply campus in Rensselaer, NY, a suburb of the state capitol of Albany, where the company carries out cGMP manufacturing for approved therapeutic proteins and those involved in clinical studies.

“Continued growth and success”

“The scale reflects the continued growth and success of the company. Over the past ten years, our team has produced numerous FDA-approved medicines, an expansive investigational pipeline, and exciting next-generation research initiatives like the Regeneron Genetics Center [RGC],” Regeneron spokeswoman Alexandra Bowie told GEN. “This new investment in our workforce and laboratory spaces will allow for continued advancement of our industry-leading scientific capabilities and diverse portfolio of medicines.”

https://www.genengnews.com/news/rege...-hq-expansion/